Signant - ActiGraph
Signant Health Holding Corp (**Signant**) proposes to acquire 100% of the shares in ActiGraph Holdings, LLC (together with its subsidiaries, **ActiGraph**). Signant is a US-based evidence generation company that provides services used in clinical trials. Signant does not have a physical presence in Australia but provides electronic clinical outcome assessments (**eCOA**), clinical trial randomisation and supply management (**RTSM**) services, and supplementary clinical trial professional services. Signant supplies these services to both contract research organisations (**CROs**) and directly to pharmaceutical and biotechnology companies. Ametris (formerly ActiGraph) is a US-based provider of digital health technology (**DHT**) for clinical trials, specialising in wearables – in particular, wrist-worn wearables and other sensors – which track biovitals and other digital endpoints for patients participating in clinical trials. Ametris does not have a physical presence in Australia but supplies its DHT products in Australia for non-commercial academic research.
- Status
- Assessment completed
- ACCC determination
- Approved
- Stage
- Waiver application
- Notified
- 10 April 2026
- Determination published
- 16 April 2026
Acquirers
- Signant Health Holding Corp.
Targets
- ActiGraph Holdings, LLC